Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026

(NASDAQ: VERU) Veru Inc. announced that its Chief Scientific Officer, Dr. Gary Barnette, will deliver a podium presentation at ObesityWeek 2026 in Washington DC, presenting results from a post hoc analysis of physical function in patients aged 65 years and older with obesity receiving a GLP-1 RA from the positive Phase 2b QUALITY study. The presentation, titled 'Enobosarm in Patients with Obesity on Semaglutide: Quality Weight Loss & Better Physical Function,' is scheduled for November 16, 2026, from 5:15 PM to 5:30 PM Eastern Standard Time. Veru's drug development program includes two late-stage novel small molecules: enobosarm, an oral selective androgen receptor modulator (SARM), and sabizabulin, an oral microtubule targeting agent. Enobosarm is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, aiming to improve body composition and physical function and to achieve clinically meaningful incremental weight reduction versus GLP-1 RA therapy alone. Sabizabulin has demonstrated potential in preclinical and clinical studies to become a treatment for KRAS-driven metastatic pancreatic cancer resistant to daraxonrasib. The company plans to pursue a Phase 2b clinical study to evaluate sabizabulin in metastatic pancreatic cancer after daraxonrasib failure and will seek regulatory clarity from the FDA through a preIND meeting in Q4 2026. The Phase 2b PLATEAU clinical trial, a double-blind, placebo-controlled study, evaluates enobosarm 3mg in older patients (age ≥ 65 years) with obesity (BMI ≥ 35) initiating semaglutide treatment. The company exceeded its targeted full enrollment of 200 patients by enrolling 239 patients. The primary efficacy endpoint is percent change from baseline in total body weight at 68 weeks, with key secondary endpoints including total fat mass, total lean mass, physical function, mobility disability assessment, bone mineral density, and patient-reported outcomes for physical function, HbA1c, and insulin resistance. Interim analysis results assessing lean body mass and fat mass after 32 weeks are expected in Q1 2027, and final topline clinical data is expected in Q4 2027. The Principal Investigator for the PLATEAU trial is Steven Heymsfield, MD, who was also the Principal Investigator for the Phase 2 QUALITY clinical study. The completed Phase 2b QUALITY clinical study was a positive multicenter, double-blind, placebo-controlled, randomized, dose-finding trial evaluating enobosarm 3 mg, enobosarm 6 mg, or placebo in 168 older patients (≥60 years) receiving semaglutide for weight reduction. After 16 weeks, participants entered a maintenance extension where all discontinued semaglutide but continued on placebo or enobosarm for 12 weeks. The study demonstrated that enobosarm plus semaglutide preserved lean mass and physical function and led to greater fat loss during the active weight loss period, and enobosarm monotherapy prevented weight regain and continued fat mass loss after GLP-1 RA discontinuation. Pancreatic cancer is projected to have 67,530 new cases and 52,740 deaths in the United States in 2026, with only ~12.5 % of patients expected to survive 5 years following diagnosis. Only 15—20% of patients are eligible for surgery, and up to 85 % present with locally advanced or metastatic disease. More than 90% of pancreatic cancer tumors have a KRAS oncogene mutation. βIII-tubulin aberrant expression is commonly observed in up to 90% of pancreatic adenocarcinoma cancers.